Shattuck Labs Announces Participation in Upcoming March Conferences
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced participation in two virtual investor conferences in March 2022. The first conference is the 42nd Annual Cowen Healthcare Conference on March 9, featuring a panel discussion on ovarian cancer, presented by Chief Medical Officer Lini Pandite. The second is Oppenheimer's 32nd Annual Healthcare Conference on March 15, with a corporate presentation by Conor Richardson, Senior Director of Finance. Both presentations will be available via live webcast and archived for 90 days.
- Participation in two reputable investor conferences may enhance visibility and attract potential investors.
- Presentations focusing on innovative cancer treatment developments could bolster investor interest.
- None.
AUSTIN, TX and DURHAM, NC, March 02, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two virtual investor conferences in March 2022.
Presentation Details
Conference: 42nd Annual Cowen Healthcare Conference
Format: Ovarian Cancer Panel Discussion
Presenter: Lini Pandite, MBChB, M.B.A., Shattuck’s Chief Medical Officer
Date: March 9, 2022
Time: 12:50 p.m. ET
Conference: Oppenheimer’s 32nd Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Conor Richardson, Shattuck’s Senior Director of Finance and Investor Relations
Date: March 15, 2022
Time: 3:20 p.m. ET
A live webcast of both presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
FAQ
What conferences is Shattuck Labs participating in?
Who will present at the Cowen Healthcare Conference?
What is the focus of the presentations from Shattuck Labs?
When can I access the recordings of the presentations?
What is the stock symbol for Shattuck Labs?
